Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
(1) Alhallak K (2) Sun J (3) Wasden K (4) Guenthner N (5) O'Neal J (6) Muz B (7) King J (8) Kohnen D (9) Vij R (10) Achilefu S (11) DiPersio JF (12) Azab AK
Lymphopenia and intratumoral lymphocytic balance in the era of cancer Immuno-Radiotherapy
(1) Koukourakis MI (2) Giatromanolaki A
(1) Koukourakis MI (2) Giatromanolaki A
Author Info: (1) Department of Radiotherapy / Oncology, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece. Electronic address: targ@her.forthnet.gr. (2) Department
Author Info: (1) Department of Radiotherapy / Oncology, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece. Electronic address: targ@her.forthnet.gr. (2) Department of Pathology, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece.
Citation: Crit Rev Oncol Hematol 2021 Jan 19 103226 Epub01/19/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33482348
CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma
(1) Lai C (2) Coltart G (3) Shapanis A (4) Healy C (5) Alabdulkareem A (6) Selvendran S (7) Theaker J (8) Sommerlad M (9) Rose-Zerilli M (10) Al-Shamkhani A (11) Healy E
(1) Lai C (2) Coltart G (3) Shapanis A (4) Healy C (5) Alabdulkareem A (6) Selvendran S (7) Theaker J (8) Sommerlad M (9) Rose-Zerilli M (10) Al-Shamkhani A (11) Healy E
Author Info: (1) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. (2) De
Author Info: (1) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. (2) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. (3) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. (4) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. (5) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. (6) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK. (7) Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. (8) Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. (9) Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. Institute for Life Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. (10) Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. Centre for Cancer Immunology, University of Southampton, Southampton, UK. (11) Dermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK e.healy@soton.ac.uk. Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Citation: J Immunother Cancer 2021 Jan 9: Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33479027
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)
(1) Slingluff CL Jr (2) Petroni GR (3) Chianese-Bullock KA (4) Wages NA (5) Olson WC (6) Smith KT (7) Haden K (8) Dengel LT (9) Dickinson A (10) Reed C (11) Gaughan EM (12) Grosh WW (13) Kaur V (14) Varhegyi N (15) Smolkin M (16) Galeassi NV (17) Deacon D (18) Hall EH
(1) Slingluff CL Jr (2) Petroni GR (3) Chianese-Bullock KA (4) Wages NA (5) Olson WC (6) Smith KT (7) Haden K (8) Dengel LT (9) Dickinson A (10) Reed C (11) Gaughan EM (12) Grosh WW (13) Kaur V (14) Varhegyi N (15) Smolkin M (16) Galeassi NV (17) Deacon D (18) Hall EH
Author Info: (1) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA cls8h@virginia.edu. University of Virginia Cancer Center, Charlottesville, Virg
Author Info: (1) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA cls8h@virginia.edu. University of Virginia Cancer Center, Charlottesville, Virginia, USA. (2) University of Virginia Cancer Center, Charlottesville, Virginia, USA. Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (3) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. University of Virginia Cancer Center, Charlottesville, Virginia, USA. (4) University of Virginia Cancer Center, Charlottesville, Virginia, USA. Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (5) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (6) Office of Research Cores Administration, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (7) University of Virginia Cancer Center, Charlottesville, Virginia, USA. University of Virginia School of Medicine, Charlottesville, Virginia, USA. (8) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. University of Virginia Cancer Center, Charlottesville, Virginia, USA. (9) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (10) Department of Gynecology and Obstetrics, Emory University, Atlanta, GA, USA. (11) Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (12) Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (13) Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (14) Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (15) Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (16) Cardiovascular Imaging Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (17) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. (18) Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. University of Virginia Cancer Center, Charlottesville, Virginia, USA.
Citation: J Immunother Cancer 2021 Jan 9: Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33479025
Global pandemics interconnected - obesity, impaired metabolic health and COVID-19
(1) Stefan N (2) Birkenfeld AL (3) Schulze MB
(1) Stefan N (2) Birkenfeld AL (3) Schulze MB
Author Info: (1) Institute of Diabetes Research and Metabolic Diseases (IDM), the Helmholtz Center, Munich, Germany. norbert.stefan@med.uni-tuebingen.de. Department of Internal Medicine IV, Div
Author Info: (1) Institute of Diabetes Research and Metabolic Diseases (IDM), the Helmholtz Center, Munich, Germany. norbert.stefan@med.uni-tuebingen.de. Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University Hospital of Tbingen, Tbingen, Germany. norbert.stefan@med.uni-tuebingen.de. German Center for Diabetes Research (DZD), Neuherberg, Germany. norbert.stefan@med.uni-tuebingen.de. (2) Institute of Diabetes Research and Metabolic Diseases (IDM), the Helmholtz Center, Munich, Germany. Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University Hospital of Tbingen, Tbingen, Germany. German Center for Diabetes Research (DZD), Neuherberg, Germany. Department of Diabetes, School of Life Course Science, King's College London, London, UK. (3) German Center for Diabetes Research (DZD), Neuherberg, Germany. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.
Citation: Nat Rev Endocrinol 2021 Jan 21 Epub01/21/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33479538
Tags:
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
(1) Hu Z (2) Leet DE (3) Alles¿e RL (4) Oliveira G (5) Li S (6) Luoma AM (7) Liu J (8) Forman J (9) Huang T (10) Iorgulescu JB (11) Holden R (12) Sarkizova S (13) Gohil SH (14) Redd RA (15) Sun J (16) Elagina L (17) Giobbie-Hurder A (18) Zhang W (19) Peter L (20) Ciantra Z (21) Rodig S (22) Olive O (23) Shetty K (24) Pyrdol J (25) Uduman M (26) Lee PC (27) Bachireddy P (28) Buchbinder EI (29) Yoon CH (30) Neuberg D (31) Pentelute BL (32) Hacohen N (33) Livak KJ (34) Shukla SA (35) Olsen LR (36) Barouch DH (37) Wucherpfennig KW (38) Fritsch EF (39) Keskin DB (40) Wu CJ (41) Ott PA
(1) Hu Z (2) Leet DE (3) Alles¿e RL (4) Oliveira G (5) Li S (6) Luoma AM (7) Liu J (8) Forman J (9) Huang T (10) Iorgulescu JB (11) Holden R (12) Sarkizova S (13) Gohil SH (14) Redd RA (15) Sun J (16) Elagina L (17) Giobbie-Hurder A (18) Zhang W (19) Peter L (20) Ciantra Z (21) Rodig S (22) Olive O (23) Shetty K (24) Pyrdol J (25) Uduman M (26) Lee PC (27) Bachireddy P (28) Buchbinder EI (29) Yoon CH (30) Neuberg D (31) Pentelute BL (32) Hacohen N (33) Livak KJ (34) Shukla SA (35) Olsen LR (36) Barouch DH (37) Wucherpfennig KW (38) Fritsch EF (39) Keskin DB (40) Wu CJ (41) Ott PA
Author Info: (1) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (2) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medica
Author Info: (1) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (2) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. (3) Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. (4) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (5) Broad Institute of MIT and Harvard, Cambridge, MA, USA. Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. (6) Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. (7) Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. (8) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. (9) Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. (10) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. (11) Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. (12) Broad Institute of MIT and Harvard, Cambridge, MA, USA. (13) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Department of Academic Haematology, University College London, London, UK. (14) Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. (15) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (16) Broad Institute of MIT and Harvard, Cambridge, MA, USA. (17) Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. (18) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (19) Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. (20) Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (21) Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (22) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (23) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (24) Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. (25) Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (26) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. (27) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. (28) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. (29) Harvard Medical School, Boston, MA, USA. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. (30) Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. (31) Broad Institute of MIT and Harvard, Cambridge, MA, USA. Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. (32) Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA. (33) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. (34) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. (35) Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark. Center for Genomic Medicine, Copenhagen University Hospital, Copenhagan, Denmark. (36) Harvard Medical School, Boston, MA, USA. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. (37) Harvard Medical School, Boston, MA, USA. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. (38) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. (39) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. (40) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Harvard Medical School, Boston, MA, USA. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. (41) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. patrick_ott@dfci.harvard.edu. Harvard Medical School, Boston, MA, USA. patrick_ott@dfci.harvard.edu. Broad Institute of MIT and Harvard, Cambridge, MA, USA. patrick_ott@dfci.harvard.edu. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. patrick_ott@dfci.harvard.edu.
Citation: Nat Med 2021 Jan 21 Epub01/21/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33479501
In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
(1) Kim S (2) Kim SA (3) Nam GH (4) Hong Y (5) Kim GB (6) Choi Y (7) Lee S (8) Cho Y (9) Kwon M (10) Jeong C (11) Kim S (12) Kim IS
(1) Kim S (2) Kim SA (3) Nam GH (4) Hong Y (5) Kim GB (6) Choi Y (7) Lee S (8) Cho Y (9) Kwon M (10) Jeong C (11) Kim S (12) Kim IS
Author Info: (1) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Sc
Author Info: (1) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (2) Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (3) Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (4) Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (5) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (6) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (7) Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (8) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (9) Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Korea University Hospital, Seoul, South Korea. (10) Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. KHU-KIST Department of Converging Science and Technology, Kyunghee University, Seoul, South Korea. (11) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea iskim14@kist.re.kr sehoonkim@kist.re.kr. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea. (12) KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, South Korea iskim14@kist.re.kr sehoonkim@kist.re.kr. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea.
Citation: J Immunother Cancer 2021 Jan 9: Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33479026
Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy
(1) Poznanski SM (2) Ritchie TM (3) Fan IY (4) El-Sayes A (5) Portillo AL (6) Ben-Avi R (7) Rojas EA (8) Chew MV (9) Shargall Y (10) Ashkar AA
(1) Poznanski SM (2) Ritchie TM (3) Fan IY (4) El-Sayes A (5) Portillo AL (6) Ben-Avi R (7) Rojas EA (8) Chew MV (9) Shargall Y (10) Ashkar AA
Author Info: (1) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (2) McMaster Immunology Research Centre, Department of Medicine, Mc
Author Info: (1) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (2) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (3) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (4) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (5) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (6) Surgery, McMaster University, Hamilton, Ontario, Canada. (7) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (8) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. (9) Surgery, McMaster University, Hamilton, Ontario, Canada. (10) McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada ashkara@mcmaster.ca.
Citation: J Immunother Cancer 2021 Jan 9: Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33479024
Non-Viral Gene Delivery to T Cells with Lipofectamine LTX
(1) Harris E (2) Zimmerman D (3) Warga E (4) Bamezai A (5) Elmer J
(1) Harris E (2) Zimmerman D (3) Warga E (4) Bamezai A (5) Elmer J
Author Info: (1) Department of Chemical & Biological Engineering, Villanova University, 800 East Lancaster Avenue, Villanova, PA, USA, 19085. (2) Department of Chemical & Biological Engineering
Author Info: (1) Department of Chemical & Biological Engineering, Villanova University, 800 East Lancaster Avenue, Villanova, PA, USA, 19085. (2) Department of Chemical & Biological Engineering, Villanova University, 800 East Lancaster Avenue, Villanova, PA, USA, 19085. (3) Department of Chemical & Biological Engineering, Villanova University, 800 East Lancaster Avenue, Villanova, PA, USA, 19085. (4) Department of Biology, Villanova University, 800 East Lancaster Avenue, Villanova, PA, USA, 19085. (5) Department of Chemical & Biological Engineering, Villanova University, 800 East Lancaster Avenue, Villanova, PA, USA, 19085.
Citation: Biotechnol Bioeng 2021 Jan 22 Epub01/22/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33480049
Tags:
Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
(1) Economopoulou P (2) Anastasiou M (3) Papaxoinis G (4) Spathas N (5) Spathis A (6) Oikonomopoulos N (7) Kotsantis I (8) Tsavaris O (9) Gkotzamanidou M (10) Gavrielatou N (11) Vagia E (12) Kyrodimos E (13) Gagari E (14) Giotakis E (15) Delides A (16) Psyrri A
(1) Economopoulou P (2) Anastasiou M (3) Papaxoinis G (4) Spathas N (5) Spathis A (6) Oikonomopoulos N (7) Kotsantis I (8) Tsavaris O (9) Gkotzamanidou M (10) Gavrielatou N (11) Vagia E (12) Kyrodimos E (13) Gagari E (14) Giotakis E (15) Delides A (16) Psyrri A
Author Info: (1) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (2) Sect
Author Info: (1) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (2) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (3) Second Department of Medical Oncology, Agios Savas Anticancer Hospital, 11522 Athens, Greece. (4) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (5) Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (6) Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (7) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (8) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (9) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (10) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (11) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. (12) Department of Otolaryngology-Head and Neck Surgery, Hippokration General Hospital, University of Athens, 11527 Athens, Greece. (13) Oral Medicine Clinics, A. Syggros Hospital of Dermatologic and Venereal Diseases, Department of Dermatology, School of Medicine, University of Athens, 16121 Athens, Greece. (14) Department of Otorhinolaryngology, Facial Plastic and Reconstructive Surgery, Stdtisches Klinikum Karlsruhe, 76133 Karlsruhe, Germany. (15) Second Otolaryngology Department, Attikon University Hospital, 12462 Athens, Greece. (16) Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece.
Citation: Cancers (Basel) 2021 Jan 14 13: Epub01/14/2021
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33466719